You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 23, 2024

Details for Patent: 11,382,917


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 11,382,917 protect, and when does it expire?

Patent 11,382,917 protects TADLIQ and is included in one NDA.

This patent has nine patent family members in nine countries.

Summary for Patent: 11,382,917
Title:Liquid oral formulations for tadalafil
Abstract: The present disclosure is directed to pharmaceutical compositions comprising a PDE V inhibitor and one or more pharmaceutical excipients or additives wherein the pharmaceutical compositions are in the form of liquid pharmaceutical compositions. The pharmaceutical compositions of the present disclosure are useful for the treatment of diseases or conditions which are treatable by administration of PDE V inhibitor drug such as pulmonary arterial hypertension, erectile dysfunction, etc.
Inventor(s): Pandya; Jinal (Unjha, IN), Mehta; Sandip P. (Ahmedabad, IN), Umrethia; Manish (Ahmedabad, IN), Mandal; Jayanta Kumar (Ahmedabad, IN), Pansuriya; Hiren (Ahmedabad, IN)
Assignee: LIQMEDS WORLDWIDE LIMITED (Haynes, GB)
Application Number:17/403,282
Patent Claim Types:
see list of patent claims
Use; Composition;

Drugs Protected by US Patent 11,382,917

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Cmp Dev Llc TADLIQ tadalafil SUSPENSION;ORAL 214522-001 Jun 17, 2022 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y TADLIQ IS INDICATED FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH) (WHO GROUP 1) TO IMPROVE EXERCISE ABILITY ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 11,382,917

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
India201721046640Dec 26, 2017
India201821012438Apr 2, 2018

International Family Members for US Patent 11,382,917

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2018397436 ⤷  Sign Up
Brazil 112020012986 ⤷  Sign Up
Canada 3086881 ⤷  Sign Up
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.